Industry
Biotechnology
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Loading...
Open
17.93
Mkt cap
661M
Volume
107K
High
17.93
P/E Ratio
13.48
52-wk high
21.79
Low
17.26
Div yield
N/A
52-wk low
11.35
Portfolio Pulse from
December 11, 2024 | 3:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 09, 2024 | 11:15 am
Portfolio Pulse from Benzinga Newsdesk
August 26, 2024 | 2:54 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 10:55 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 2:34 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:20 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:18 am
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 10:52 am
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 11:20 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.